Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Excretion Clear all

Conditions: Prostate Cancer, Bone Metastases
Interventions: [68Ga]P15-041; Drug
Lead sponsor: Five Eleven Pharma, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy
Interventions: 14C-JNJ-56136379; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: PF-04991532; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Premature Ventricular Contractions, Congestive Heart Failure
Interventions: PVC ablation; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 7
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Postpartum, Lactation, Drugs in Breast Milk, Mammary Drug Transporters, BCRP, OCT1
Interventions: Cimetidine 200 MG; Drug
Lead sponsor: University of Washington; Other
Eligibility: 14 Days to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: ADHD, Fibromyalgia
Interventions: TD-9855; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: [14C]Elpipodect; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acinetobacter Baumannii-calcoaceticus Complex Infections
Interventions: ETX2514, 14C-ETX2514; Drug
Lead sponsor: Entasis Therapeutics; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anemia, Sickle Cell
Interventions: GBT440; Drug
Lead sponsor: Global Blood Therapeutics; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Nocturnal Enuresis
Interventions: Lully Sleep Guardian; Device
Lead sponsor: Indiana University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Fecal Incontinence, Anal Incontinence
Interventions: Biodesign Tissue Repair Graft, Overlapping Sphincter Repair; Device · Other
Lead sponsor: Massarat Zutshi; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Stress Urinary Incontinence
Interventions: AMDC-USR (iltamiocel), Placebo; Biological · Other
Lead sponsor: Cook MyoSite; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 20
States / cities: Tucson, Arizona • La Mesa, California • Los Angeles, California + 17 more

Conditions: Migraine Disease, Patent Foramen Ovale
Interventions: Prasugrel 5mg, Transcatheter Closure of Patent Foramen Ovale; Drug · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: [14C]-plazomicin; Drug
Lead sponsor: Achaogen, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Obstetric Labour, Premature, Premature Labor
Interventions: GSK221149A; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Constipation, Incontinence Bowel
Interventions: Paper diary, Electronic APP diary; Other
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies
Interventions: LBH589; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Diabetic Foot Ulcer
Interventions: Noveon laser; Device
Lead sponsor: Nomir Medical Technologies; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Renal Excretion, Bacterial Infections, Inflammatory Disease, Oncologic Disease
Interventions: 11C-para-aminobenzoic acid PET/CT, Probenecid; Combination Product · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: PD-0332991 alone, Tamoxifen 60 mg, Tamoxifen 20 mg, PD-0332991 combination; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Safety and Pharmacokinetics in Healthy Volunteer Subjects
Interventions: CC-223; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: [14C]-HU6; Drug
Lead sponsor: Rivus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autism, Food Allergies
Interventions: Acupressure treatments and NAET treatments; Procedure
Lead sponsor: Nambudripad's Allergy Research Foundation; Other
Eligibility: 3 Years to 10 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Buena Park, California

Search by objective public record fields.

Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041

Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants

Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532

Early Elimination of Premature Ventricular Contractions in Heart Failure

Drug Excretion in Breast Milk

TD-9855 Mass Balance Study

A Study of Elpipodect (MK-8189) Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)

Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects

A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects

Scheduled Awakenings for the Treatment of Nocturnal Enuresis

Comparison of the Efficacy of a Biological Implant to Reinforce Overlapping Sphincter Repair Versus Overlapping Sphincter Repair Alone

Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy

A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin

Absorption, Distribution, Metabolism And Excretion Study For GSK221149A

Electronic Mobile Phone App Stool Diary

A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589

Bioburden Reduction of Diabetic Foot Ulcer

Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid

A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects

A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6

An Autism Study Using Nambudripad's Food Allergy Elimination Treatments